Capricor Therapeutics is an American clinical stage biotechnology company. The company focuses on the development and commercialization of biological therapies for the treatment of duchenne muscular dystrophy (DMD) and other rare disorders. Capricor Therapeutics serves healthcare sector in the United States and Canada.
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential
Capricor Therapeutics news
11.05.2022
Capricor Therapeutics reported a GAAP loss of $7.818 million for the 3 months of 2022, up 51.7% from $5.152 million in the prior year. The company did not generate revenue. A year earlier the figure was $40,816 thousand.
Source: app.quotemedia.com
11.03.2022
Capricor Therapeutics' GAAP loss for 2021 was $20.023 million, up 46.6% from $13.657 million the previous year. Revenue was down 21.1% to $244,898,000 from $310,25,000 a year earlier.
Source: feeds.issuerdirect.com
10.11.2021
Capricor Therapeutics' GAAP loss for 9M 2021 was $13.832 million, up 45.9% from $9.479 million in the prior year. Revenue decreased 3% to $244,898,000 from $252,42,000 a year earlier.
Source: 
irdirect.net
irdirect.net
13.08.2021
Capricor Therapeutics' GAAP loss for 6M 2021 was $9.9 million, up 77.8% from $5.569 million in the prior year. Revenue increased 4% to $244,898,000 from $235,557,000 a year earlier.
Source: irdirect.net
irdirect.net
General information
| Company name | Capricor Therapeutics |
|---|---|
| Sector | Health Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology |
| Business address | 8840 WILSHIRE BLVD 2ND FLOOR BEVERLY HILLS CA 90211 (310) 358-3200 |
| Mailing address | 8840 WILSHIRE BLVD 2ND FLOOR BEVERLY HILLS CA 90211 |
| Website | capricor.com |
| Information disclosure | www.sec.gov |
English (US) 